Update – Systemische juvenile Arthritis

ZUSAMMENFASSUNG

Die systemische juvenile idiopathische Arthritis nimmt unter den Kategorien der JIA eine Sonderstellung ein, klinisch aufgrund der obligat extraartikulären, systemischen Beteiligung, aber auch aufgrund der der vital bedrohlichen Komplikationen, Makrophagenaktivierungssyndrom und Lungenbeteiligung. Untersuchungen legen ein biphasisches Krankheitsgeschehen mit konsekutiven Eigenschaften einer autoinflammatorischen mit denen einer Autoimmunerkrankung nahe. Diese Erkenntnisse führten zu Therapieoptionen wie der IL-1- und IL-6-Blockade mit Biologika und zu Therapiealgorithmen, die zwischen früher Erkrankung und später Erkrankung unterscheiden, letztlich mit dem Ziel, der Nutzung eines „windows of opportunity“ zur Erreichung des Therapieziels der Remission.

Publication History

Article published online:
18 October 2021

• Literatur

• 1 Martini A, Ravelli A, Avcin T. et al Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 2019; 46 (02) 190-197
• 2 Canna SW, Schulert GS, de Jesus A. et al Proceedings from the 2(nd) Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3–4, 2019. Pediatr Rheumatol Online J 2020; 18 (Suppl. 01) 53
• 3 Gattorno M, Piccini A, Lasiglie D. et al The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58 (05) 1505-1515
• 4 Ter Haar NM, van Dijkhuizen EHP, Swart JF. et al Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis Rheumatol 2019; 71 (07) 1163-1173
• 5 Pardeo M, Pires Marafon D, Insalaco A. et al Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience. J Rheumatol 2015; 42 (08) 1523-1527
• 6 Horneff G, Schulz AC, Klotsche J. et al Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther 2017; 19 (01) 256
• 7 Saccomanno B, Tibaldi J, Minoia F. et al Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. J Rheumatol 2019; 46 (04) 416-421
• 8 Pacharapakornpong T, Vallibhakara SA, Lerkvaleekul B, Vilaiyuk S. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis. Rheumatol Int 2017; 37 (02) 251-255
• 9 Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 2013; 61 (02) 345-348
• 10 Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81 (01) 28-37
• 11 Holzinger D, Frosch M, Kastrup A. et al The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2012; 71 (06) 974-980
• 12 Föll D, Wittkowski H, Hinze C. Das Still-Syndrom als biphasische Erkrankung. Zeitschrift für Rheumatologie 2020; 79 (07) 639-648
• 13 Kessel C, Hedrich CM, Foell D. Innately Adaptive or Truly Autoimmune: Is There Something Unique About Systemic Juvenile Idiopathic Arthritis?. Arthritis Rheumatol 2020; 72 (02) 210-219
• 14 Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011; 07 (07) 416-426
• 15 Nigrovic PA, Mannion M, Prince FH. et al Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63 (02) 545-555
• 16 Behrens EM, Beukelman T, Gallo L. et al Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 2008; 35 (02) 343-348
• 17 Gurion R, Lehman TJ, Moorthy LN. Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam 2012; 2012: 271569
• 18 Frosch M, Metze D, Foell D. et al Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp Dermatol 2005; 14 (04) 259-265
• 19 Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol 1998; 12 (02) 245-271
• 20 Behrens EM. Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell?. Autoimmun Rev 2008; 07 (04) 305-308
• 21 Minoia F, Davi S, Horne A. et al Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014; 66 (11) 3160-3169
• 22 Saper VE, Chen G, Deutsch GH. et al Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis 2019; 78 (12) 1722-1731
• 23 Dong S, Bout-Tabaku S, Texter K, Jaggi P. Diagnosis of systemic-onset juvenile idiopathic arthritis after treatment for presumed Kawasaki disease. J Pediatr 2015; 166 (05) 1283-1288
• 24 Limenis E, Feldman BM, Achonu C. et al Proposed Core Set of Items for Measuring Disease Activity in Systemic Juvenile Idiopathic Arthritis. J Rheumatol 2018; 45 (01) 115-121
• 25 Foell D, Wittkowski H, Hammerschmidt I. et al Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 2004; 50 (04) 1286-1295
• 26 Gohar F, McArdle A, Jones M. et al Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. Ann Rheum Dis 2019; 78 (08) 1107-1113
• 27 Gohar F, Kessel C, Lavric M. et al Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?. Arthritis Res Ther 2016; 18: 163
• 28 Wittkowski H, Frosch M, Wulffraat N. et al S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 2008; 58 (12) 3924-3931
• 29 Rothmund F, Gerss J, Ruperto N. et al Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2014; 66 (06) 949-955
• 30 Aljaberi N, Tronconi E, Schulert G. et al The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatr Rheumatol Online J 2020; 18 (01) 7
• 31 Yasin S, Fall N, Brown RA. et al IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology (Oxford) 2020; 59 (02) 361-366
• 32 Kudela H, Drynda S, Lux A. et al Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatol 2019; 03: 4
• 33 Lee PY, Schulert GS, Canna SW. et al Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis 2020; 79 (02) 225-231
• 34 Bracaglia C, de Graaf K, Pires Marafon D. et al Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis 2017; 76 (01) 166-172
• 35 Eloseily EMA, Minoia F, Crayne CB. et al Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. ACR Open Rheumatol 2019; 01 (06) 345-349
• 36 Tibaldi J, Pistorio A, Aldera E. et al Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2020; 59 (11) 3505-3514
• 37 Vastert SJ, Jamilloux Y, Quartier P. et al Anakinra in children and adults with Still’s disease. Rheumatology (Oxford) 2019; 58 (Suppl. 06) vi9-vi22
• 38 Hinze CH, Holzinger D, Lainka E. et al Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J 2018; 16 (01) 7
• 39 Hinze C, Kubasch AS, Berner R, Föll D. Systemische juvenile idiopathische Arthritis. Monatsschr Kinderheilkd 2018; 166 (10) 905-907
• 40 Nigrovic PA, Beukelman T, Tomlinson G. et al Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). Clin Trials 2018; 15 (03) 268-277
• 41 Kimura Y, Grevich S, Beukelman T. et al Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. Pediatr Rheumatol Online J 2017; 15 (01) 23
• 42 Atemnkeng Ntam V, Klein A, Horneff G. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis – data from the German BIKER registry. Expert Opin Drug Saf 2021; 20 (01) 93-100
• 43 Arthur VL, Shuldiner E, Remmers EF. et al IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol 2018; 70 (08) 1319-1330
• 44 Hinze C, Fuehner S, Kessel C. et al Impact of IL1RN Variants on Response to Interleukin-1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol 2020; 72 (03) 499-505
• 45 Brunner HI, Quartier P, Alexeeva E. et al Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. Arthritis Rheumatol 2020; 72 (12) 2147-2158
• 46 Ruperto N, Brunner HI, Quartier P. et al Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis 2018; 77 (12) 1710-1719
• 47 Feist E, Quartier P, Fautrel B. et al Efficacy and safety of canakinumab in patients with Still’s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol 2018; 36 (04) 668-675
• 48 De Benedetti F, Brunner HI, Ruperto N. et al Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367 (25) 2385-2395
• 49 Mallalieu NL, Wimalasundera S, Hsu JC. et al Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatr Rheumatol Online J 2019; 17 (01) 57
• 50 Malattia C, Ruperto N, Pederzoli S. et al Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. Arthritis Res Ther 2020; 22 (01) 211
• 51 Pardeo M, Wang J, Ruperto N. et al Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. J Rheumatol 2019; 46 (09) 1117-1126
• 52 Gupta A, Bagri NK, Tripathy SK. et al Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis. Rheumatol Int 2020; 40 (01) 153-159
• 53 Kiltz U, Kiefer D, Braun J. et al Prolonged treatment with Tadekinig alfa in adult-onset Still’s disease. Ann Rheum Dis 2020; 79 (01) e10
• 54 Gabay C, Fautrel B, Rech J. et al Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 2018; 77 (06) 840-847
• 55 Bader-Meunier B, Hadchouel A, Berteloot L. et al Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report. 2020: 216983
• 56 Huang Z, Lee PY, Yao X, Zheng S, Li T. Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis. Pediatrics 2019; 143 (05) e20182845
• 57 Hu Q, Wang M, Jia J. et al Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China. Ann Rheum Dis 2020; 79 (06) 842-844
• 58 Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990 s. Rheum Dis Clin North Am 1991; 17 (04) 891-905
• 59 Minden K, Kiessling U, Listing J. et al Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol 2000; 27 (09) 2256-2263
• 60 Oen K, Malleson PN, Cabral DA. et al Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002; 29 (09) 1989-1999
• 61 Wallace CA, Huang B, Bandeira M. et al Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005; 52 (11) 3554-3562